Designation as an essential medicine expresses a policy priority, yet it does not by itself establish that a patient can obtain an appropriate, quality-assured product when treatment is needed. Access emerges from several functions that operate under different institutional responsibilities and can fail independently or interact. Selection determines which medicines receive formal priority; financing and procurement determine whether that priority becomes a sustainable purchasing commitment; quality assurance determines whether available products are suitable for use; distribution determines whether procured stock reaches facilities reliably; and dispensing conditions and household resources determine whether a patient can ultimately obtain treatment. Failure at one function may also shift burdens downstream. A public-sector stockout can redirect demand toward higher-priced private outlets, procurement choices can alter the market for substitute products, and inadequate formal access can encourage medicine purchasing through less controlled channels. Conversely, interventions that remove patient charges can improve adherence while leaving other determinants of clinical outcomes unresolved. This policy analysis disaggregates these functions and examines how their interaction can explain the recurrent gap between formal essential-medicine policy and patient-level treatment access. It argues for function-specific diagnosis and measurement rather than treating listing, availability, affordability, quality, and treatment continuity as interchangeable manifestations of a single access problem.
